Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
ARS Pharmaceuticals is a stealth pharmaceutical company that specializes in developing anti allergy drugs.
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.
Dren Bio focuses on protein engineering technologies for depletion of cells, protein aggregates, and other disease-causing agents.
Crystalys Therapeutics is a clinical-stage biopharmaceutical company that develops targeted therapies for gout and hyperuricemia.
Renalys Pharma is a clinical-stage biopharmaceutical company developing therapeutics for renal disease in Asian patients.
Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Draig Therapeutics is a clinical-stage biopharmaceutical company that develops investigational therapies for neuropsychiatric disorders.
Ancora Biotech is a privately held company supporting the clinical development of three multi-specific antibodies.
MiroBio is Harnessing the natural control mechanisms of the immune system.
Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.
VeraDermics is a dermatology company that creates novel drug delivery mechanisms for a pain-free cure for skin conditions.
Immutrin is a biotech developing next‑generation antibody therapies to clear amyloid deposits and reverse amyloidosis.
MISSION Therapeutics develops therapies that enhance the removal of dysfunctional mitochondria to combat serious diseases.
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.
Akamis Bio is a clinical-stage oncology company.
Nomic develops a proteomic technology platform to understand, detect, and treat diseases with DNA nanotechnology.
Elektrofi is a preclinical-stage company dedicated to redefining the standard of drug delivery by transforming the patient experience.
AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions.
Poplar Therapeutics anti-IgE therapy treats atopic diseases such as food allergy, allergic asthma, and atopic dermatitis.
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer.
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.
Antag Therapeutics provides therapeutic peptides for the treatment of dietary-related metabolic diseases.
SR One has invested in 65 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
SR One's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 16 different industry categories.
Among tracked funding rounds, VeraDermics received $384.4M in a Post-IPO Equity round. SR One's total known invested capital is $4.6B.
SR One's average investment size is $97.5M across its portfolio of 65 companies.
Recent SR One portfolio additions include ARS Pharmaceuticals, Fore Biotherapeutics, Dren Bio, Crystalys Therapeutics, Renalys Pharma. These companies were founded in 2020 or later.